Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

明通 - NMPA Drug Approval Details

Approvals/NMPA/明通

Approved

中药

明通

Unknown🇨🇳 National Medical Products Administration

Approval Date: Oct 14, 2022
Approval ID: 2fb6caf8e6962e2d
Company: Unknown
Type: 中药

Approval Details

Approval Id: 2fb6caf8e6962e2d
Approval Number: 国药准字ZC20171003
Generic Name: 治伤风颗粒
Brand Name: 明通
Drug Type: 中药
Dosage Form: 颗粒剂
Strength: 每袋装2g(相当于饮片1.236g,含对乙酰氨基酚240mg,咖啡因50mg,盐酸那可丁10mg,马来酸氯苯那敏2mg)
Reg Date: 2022-10-14
Expired Date: 2027-10-13
Production Company Address: 台湾省台中市工业区21路15号

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Oct 14, 2022

Approval ID

2fb6caf8e6962e2d

Type

中药

Back to NMPA Approvals